Ewa Konca, MD
Endocrinology, Diabetes & Metabolism · Pomona, CANPI 1134197528
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,850 of the $55,255 with a category attached, or 68.5%. 56 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 37.0% of the total. Reporting peaked in 2019 at $20,343 and has fallen 85.9% since, to $2,870 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 928 payments — averaging $59.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$20K
- Johnson & Johnson$13K
- Lilly USA, LLC$10K
- Amgen$2K
- Novo Nordisk$1K
- AstraZeneca$918
- plus $9K from 50 others
Across 2 payments — averaging $19,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$39K
What the payments were for
- Speaking & faculty fees$37,85069%
- Travel & lodging$1,4043%
- Food & beverage$15,90529%
- Education$360%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,255 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 358 | $370,561 |
| TrulicityDulaglutide | 256 | $290,724 |
| FarxigaDapagliflozin Propanediol | 365 | $284,490 |
| JardianceEmpagliflozin | 306 | $236,382 |
| MounjaroTirzepatide | 95 | $109,002 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $71,860 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 55 | $47,168 |
| ProliaDenosumab | 27 | $44,661 |
| TymlosAbaloparatide | 13 | $41,664 |
| InvokanaCanagliflozin | 27 | $25,882 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 24 | $24,623 |
| Wellbutrin XlBupropion Hcl | 11 | $23,785 |
| JanuviaSitagliptin Phosphate | 25 | $23,425 |
| DapagliflozinDapagliflozin Propanediol | 36 | $19,393 |
| RybelsusSemaglutide | 15 | $15,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $9,745 | $399,726351 claims |
| Novo NordiskOzempic, Rybelsus | $1,048 | $386,069373 claims |
| AstraZenecaFarxiga | $918 | $284,490365 claims |
| Boehringer IngelheimJardiance | $505 | $236,382306 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $20,472 | $47,16855 claims |
| AmgenProlia | $1,905 | $44,66127 claims |
| Radius Health, Inc.Tymlos | $706 | $41,66413 claims |
| MerckJanuvia, Steglatro | $283 | $32,67446 claims |
| Johnson & JohnsonInvokana | $12,605 | $25,88227 claims |
| AbbVieLinzess, Synthroid | $236 | $15,05998 claims |
| NovartisEntresto | $389 | $7,28511 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $29 | $5,669487 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Pomona
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.